tiprankstipranks
Advertisement
Advertisement
Enlivex Reveals $1.1 Billion RAIN Token Treasury and $66.16 NAV Per Share
PremiumCompany AnnouncementsEnlivex Reveals $1.1 Billion RAIN Token Treasury and $66.16 NAV Per Share
11d ago
Enlivex Wins FDA RMAT Status for Allocetra in Age-Related Knee Osteoarthritis
Premium
Company Announcements
Enlivex Wins FDA RMAT Status for Allocetra in Age-Related Knee Osteoarthritis
18d ago
Enlivex Therapeutics receives RMAT designation for Allocetra from FDA
Premium
The Fly
Enlivex Therapeutics receives RMAT designation for Allocetra from FDA
18d ago
Enlivex Values RAIN Token Treasury at $1.14 Billion as of June 20, 2026
PremiumCompany AnnouncementsEnlivex Values RAIN Token Treasury at $1.14 Billion as of June 20, 2026
1M ago
Enlivex Therapeutics announces issuance of Australian patent
Premium
The Fly
Enlivex Therapeutics announces issuance of Australian patent
2M ago
Enlivex Values RAIN Token Treasury at $1.16 Billion as Rain Protocol Climbs to No. 3 in Prediction Markets
Premium
Company Announcements
Enlivex Values RAIN Token Treasury at $1.16 Billion as Rain Protocol Climbs to No. 3 in Prediction Markets
2M ago
Enlivex Doses First U.S. Patient in Phase 2b Allocetra Trial for Knee Osteoarthritis
PremiumCompany AnnouncementsEnlivex Doses First U.S. Patient in Phase 2b Allocetra Trial for Knee Osteoarthritis
2M ago
Enlivex Therapeutics doses first patient in Allocetra trial
Premium
The Fly
Enlivex Therapeutics doses first patient in Allocetra trial
2M ago
Enlivex Faces Nasdaq Minimum Bid Price Deficiency After Shares Fall Below $1 Threshold
Premium
Company Announcements
Enlivex Faces Nasdaq Minimum Bid Price Deficiency After Shares Fall Below $1 Threshold
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100